HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
Coelho-Borges
Silvia
S
Cheinquer
Hugo
H
Cheinquer
Nelson
N
Krug
Luciano
L
Ashton-Prolla
Patrícia
P
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006680:HLA Antigens / Q000235:genetics*; D000071020:Hemochromatosis Protein; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000235:genetics*; D015395:Histocompatibility Antigens Class I / Q000235:genetics*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D019190:Iron Overload / Q000097:blood / Q000150:complications*; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D009154:Mutation / Q000502:physiology*; D012254:Ribavirin / Q000627:therapeutic use*
D000998:Antiviral Agents; D015415:Biomarkers; C103673:HFE protein, human; D006680:HLA Antigens; D000071020:Hemochromatosis Protein; D015395:Histocompatibility Antigens Class I; D008565:Membrane Proteins; D012254:Ribavirin; D007372:Interferons